THE TLR4 299GLY POLYMORPHIC ALLELE IS ASSOCIATED WITH REDUCED EFFICACY OF AZITHROMYCIN AND PIOGLITAZONE, INCLUDED IN THE COMPREHENSIVE TREATMENT OF PATIENTS WITH CORONARY HEART DISEASE
The Asp299Gly polymorphism of the TLR4 gene plays an important role in the pathogenesis of coronary heart disease (CHD). The purpose of the work is to conduct a comparative analysis of the clinical efficacy of azithromycin and pioglitazone against the background of complex therapy taking into account the Asp299Gly polymorphism of the TLR4 gene in patients with CHD. Materials and methods. The study included 40 people with CHD in the age group 45-68 years, divided into 2 groups of observation: the first group (n = 20) received, together with the integrated therapy, azithromycin at a dose of 500 mg/day for 3 days, then 500 mg/week for 6 months, the second group (n = 20) - together with the combined therapy pioglitazone in a dose of 15 mg once daily, in the morning for 6 months. Duration of observation 12 months. Results. Each observation group was divided into two subgroups: the Asp/Asp genotype and the combined genotype Asp/Gly +Gly/Gly. The first observation group with the Asp/Asp genotype was 14 (70%), while the combined genotype Asp/Gly +Gly/Gly was 6 (30%), the second observation group was 17 (85%) and 3 (15% ), respectively. The acceptance of azithromycin from Asp (Asp/Asp) allele carriers, led to a more effective reduction in the size of the ACS, the diameter of the stenosis and TSC, partial or complete eradication of the parodontopathogenic microflora in the oral cavity. The use of pioglitazone in carriers of the Asp allele (Asp/Asp) caused a more pronounced decrease in the diameter of the stenosis, moderate anti-inflammatory and pronounced hypoglycemic, hypolipidemic effects. Conclusions The data obtained by us showed that in patients with CHD, carriers of Asp allele, a high susceptibility to treatment was detected, and the presence of the Gly mutant allele of the TLR-4 gene was associated with a reduced therapeutic efficacy of the investigational drugs, against the background of a standard course of treatment, which indicates the pharmacogenetic peculiarity of susceptibility to the action of the investigational drugs and should be taken into account in clinical practice.
2. Skochko O.V. Quantitative analysis of some groups of microorganisms isolated from atherosclerotic coronary arteries of patients depending on the Asp299Gly polymorphism of TLR4 gene / O.V. Skochko, I.P. Kaidashev, L.E. Vesnina [et al.] // Likarska sprava. – 2012. – No. 3-4 (1113). – P. 82-85.
3. Skochko O.V. The role of some parodontopathogenic microorganisms and Asp299Gly polymorphism of TLR4 gene in the pathogenesis of atherosclerosis / O.V. Skochko, N.A. Bobrova, O.V. Izmailova, I.P. Kaidashev // Zhurn. mikrobiologii i epidemiologii. – 2011. – No. 5. – P. 83-85.
4. Amantea D. Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype / D.Amantea, M.Certo, F. Petrelli [et al.] // Exp. Neurol. – 2016. – Vol. 275 (Pt 1). – P. 116-125.
5. ChenR.TLR4Asp299Gly (rs4986790) polymorphismandcoronaryarterydisease: ameta-analysis /R.Chen, N.Gu, Y.Gao, W.Cen //PeerJ. – 2015. – Vol. 3. – P. e1412.
6. Hanefeld M. Anti-inﬂammatory effects of Pioglitazone and/or Simvastatin in high cardiovascular risk patients with elevated high sensitivity C-Reactive Protein. The PIOSTAT Study / M. Hanefeld, N. Marx, A. Pftzner [et al.] // J. American College of Cardiology.- 2007. – Vol. 49 (3). – Р. 290-297.
7. Kiechl S.Toll-like receptor 4 polymorphisms and atherogenesis / S.Kiechl, E. Lorenz, M. Reindl[et al.]// N. Engl. J. Med. – 2002. – Vol. 347. – P. 185–192.
8. Levchenko L. Yu. TLR4 896A/G gene polymorphism, rather than the TLR4 1196C/T and TLR2 2258G/A gene polymorphisms, determines the severe and aggravated course of atopic dermatitis in children / L. Yu. Levchenko, O. V. Izmailova, O. A. Shlykova, I. P. Kaidashev // Cytology and Genetics. – 2013. – Vol. 47(3). – P. 167–173.
9. Morita S. Pioglitazone, a peroxisome proliferator-activated receptor γ activator, suppresses coronary spasm / S. Morita, Y. Mizuno, E. Harada [et al.]// Coron. Artery Dis. – 2014. – Vol. 25(8). – P. 671-677.
10. Nitta Y. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging /Y. Nitta, N. Tahara, A. Tahara [et al.]// JACC Cardiovasc. Imaging.- 2013. – Vol. 6(11). – P. 1172-1182.
11. Schneider C.A. In vivo uptake of azithromycin in human coronary plaques / C.A. Schneider, H. Diedrichs,K.D. [et al.] // Am. J. Cardiol. – 2000. –Vol. 86 (7). – P. 789-791.
12. Schneider S. Association of Toll-like receptor 4 polymorphism with age-dependent systolic blood pressure increase in patients with coronary artery disease /S.Schneider, W.Koch, P. Hoppmannet [et al.] // Immunity Ageing. – 2015. – Vol. 12. – P. 1-4.
13. Skochko О.V. The relationship of periodontal disease to risk factors for the development of the ischemic heart disease / О.V. Skochko, T.V. Mamontova, L.E. Vesnina, I.P. Kaidashev // Ukrainian J. Cardiology. – 2015. – Vol. 2. – P. 87-94.
14. StellariF.F. Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study / F.F. Stellari, A. Sala, G. Donofrio [et al.] // Pharmacol Res Perspect. – 2014. – Vol. 2 (5). – P. e00058.
15. WangW.TLR4 activationinducesnontolerantinflamma¬toryresponseinendothelialcells / W.Wang, M.Deng,X. Liu [et al.] //J.Inflammation. – 2011. –Vol. 34(6). – P. 509-518.
Wei W.Y. Pioglitazone protected against cardiac hypertrophy via inhibiting AKT/GSK3β and MAPK signaling pathways / W.Y.Wei,Z.G.Ma,S.C.Xu [et al.] // PPAR Res.– 2016. – Vol. 2016. – P.917-941.